BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GenomeDx Biosciences Launches UroSketch 3D™, a Free Urology Patient Consult Application Designed for Use on the iPad


5/3/2013 9:40:34 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO and VANCOUVER, British Columbia, May 3, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced the launch of UroSketch 3D, an application available in Apple's App Store and designed specifically for the iPad. The app, which provides a three-dimensional model of the prostate, bladder and surrounding organs for use by physicians during consult with their patients, is now available for download and works with any iPad and iPad mini using the iOS 6 software.

UroSketch 3D was developed in collaboration with Vancouver-based Conquer Mobile and a panel of urologists and consists of preset three-dimensional model views, which allow a physician to zoom in on an image and show the image in 360-degree rotation. The application also offers illustration of different tumor stages and other features which currently focus on the prostate. Funding for this project was made possible by a grant from the Industrial Research Assistance Program (IRAP).

"Practicing urologists told us that an easy-to-use visual application would help them better communicate with their patients," said Doug Dolginow, MD, CEO of GenomeDx. "During the development process, our goal was to pay special attention to anatomical features that are relevant during discussion of prostatectomy so that physicians have another tool to communicate with their patients about the potential ramifications of prostate removal."

"The initial conversation when I first tell my patient that he has prostate cancer can be very challenging for both of us. The weight of the news makes it very difficult for him to absorb new information about his prostate cancer and any details regarding management options to follow," said Ali Kasraeian, MD, FACS, of Kasraeian Urology in Jacksonville, Florida. "I think this app will help engage the patient in his personalized prostate cancer conversation and help facilitate better communication and more effective patient understanding, especially since I can send patients home with an image that will reinforce the details of our conversation."

In each view in the UroSketch 3D app, physicians can use a draw and/or highlighter function to mark up images and then email or print out a personalized PDF for patients to take home. The resulting PDF will include a header with physician name, date stamp and any contact details that the physician provides upon download of the app. Consult sessions are listed on the home screen by time and erased at the end of each day to ensure privacy. Physicians may create master sketches, which are not erased and can be used as templates for new sessions.

Come visit GenomeDx at AUA 2013 in booth 2647 and learn more about UroSketch 3D and the Decipehr test, a transformative prognostic test that provides a measure of the biological risk of metastatic prostate cancer.

About GenomeDx Biosciences

GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that have a real impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. The company's first test, Decipher, is a transformative prognostic test that provides a direct measure of the true biological risk of metastatic prostate cancer independent of PSA and other risk factors. GenomeDx is based in San Diego, California and Vancouver, British Columbia. More information is available at www.genomedx.com.

SOURCE GenomeDx Biosciences



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES